The world's fastest LCMS/MS tandem mass spectrometer

Article

Shimadzu has introduced the LCMS-8040 which combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.

The world’s fastest LCMS/MS tandem mass spectrometer

Expanded range of ultra-fast, high-sensitivity applicationsShimadzu has introduced the LCMS-8040 which combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved in comparison to the LCMS-8030 model by improving ion focusing and minimizing ion losses between multi-pole lenses.

The fastest scan speed of 15,000 u/s and the fastest polarity switching time of 15 msec, already known from the LCMS-8030, expand in combination with the higher sensitivity the potential range of LC/MS/MS applications. The LCMS-8040 achieves multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second utilizing UFsweeper II collision cell technology. UFsweeper II features high-speed ion transport technology that maintains sensitivity and suppresses crosstalk, even for high-speed or simultaneous multi-component analyses.

LabSolutions LCMS software offers a variety of data processing features, including a Quantitation Browser which processes multiple analytes, and a Data Browser which allows users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Related Content